Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul 21;35(28):1864-72.
doi: 10.1093/eurheartj/ehu046. Epub 2014 Feb 20.

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Sigrun Halvorsen  1 , Dan Atar  2 , Hongqiu Yang  3 , Raffaele De Caterina  4 , Cetin Erol  5 , David Garcia  6 , Christopher B Granger  3 , Michael Hanna  7 , Claes Held  8 , Steen Husted  9 , Elaine M Hylek  10 , Petr Jansky  11 , Renato D Lopes  3 , Witold Ruzyllo  12 , Laine Thomas  3 , Lars Wallentin  8
Affiliations
Randomized Controlled Trial

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Sigrun Halvorsen et al. Eur Heart J. .

Abstract

Aims: The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age.

Methods and results: A total of 18 201 patients with AF and a raised risk of stroke were randomized to warfarin or apixaban 5 mg b.d. with dose reduction to 2.5 mg b.d. or placebo in 831 patients with ≥2 of the following criteria: age ≥80 years, body weight ≤60 kg, or creatinine ≥133 μmol/L. We used Cox models to compare outcomes in relation to patient age during 1.8 years median follow-up. Of the trial population, 30% were <65 years, 39% were 65 to <75, and 31% were ≥75 years. The rates of stroke, all-cause death, and major bleeding were higher in the older age groups (P < 0.001 for all). Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age (P interaction >0.11 for all). Results were also consistent for the 13% of patients ≥80 years. No significant interaction with apixaban dose was found with respect to treatment effect on major outcomes.

Conclusion: The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.

Keywords: Age; Anticoagulants; Apixaban; Atrial fibrillation; Bleeding; Stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier curves for outcomes according to age category. (A) Stroke or systemic embolism, (B) all-cause mortality, (C) ISTH major bleeding, (D) intracranial haemorrhage. ISTH, International society on Thrombosis and Haemostasis.
Figure 2
Figure 2
The effect of apixaban vs. warfarin on major study outcomes according to age. *Interaction P-values are based on continuous age.
Figure 3
Figure 3
The effect of apixaban vs. warfarin on stroke or systemic embolism and major bleeding in patients ≥75 years in relation to apixaban dose.
See this image and copyright information in PMC

Comment in

References

    1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953. - PubMed
    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375. - PubMed
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272. - PubMed
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867. - PubMed
    1. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–2696. - PubMed

Publication types

MeSH terms